Comparative Pharmacology
Head-to-head clinical analysis: CYTOXAN versus TREANDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYTOXAN versus TREANDA.
CYTOXAN vs TREANDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclophosphamide is an alkylating agent that crosslinks DNA, leading to cell cycle nonspecific cytotoxicity. It requires hepatic activation by cytochrome P450 enzymes to form active metabolites, primarily phosphoramide mustard.
Bendamustine is a bifunctional mechlorethamine derivative that forms electrophilic alkyl groups which covalently bond to DNA bases, resulting in interstrand DNA crosslinks, DNA single- and double-strand breaks, and ultimately apoptosis. It also inhibits several mitotic checkpoints and induces both apoptosis and necrosis in cancer cells.
500-1500 mg/m² IV every 2-4 weeks or 1-5 mg/kg/day PO for 10-14 days.
120 mg/m2 IV over 60 minutes on Days 1 and 2 of a 21-day cycle.
None Documented
None Documented
Terminal elimination half-life of cyclophosphamide is 3-12 hours (range 2-19 h) in adults; the half-life of active metabolites (e.g., 4-hydroxycyclophosphamide) is approximately 8-10 hours. Half-life is prolonged in hepatic impairment (up to 20 h) and reduced in dose adjustments.
Terminal elimination half-life: ~36-40 minutes (active metabolite M3: ~3 hours). Short half-life supports multi-day dosing regimens; clinical effect duration is longer due to DNA alkylation.
Renal elimination of unchanged cyclophosphamide (5-30%) and metabolites (primarily 4-ketocyclophosphamide and carboxyphosphamide) accounts for approximately 80% of total clearance; fecal excretion is minimal (<5%).
Renal: ~50% as unchanged drug and metabolites; additional biliary/fecal elimination (non-renal clearance accounts for ~50% in humans, but specific biliary/fecal percentages not routinely quantified in clinical studies).
Category C
Category C
Alkylating Agent
Alkylating Agent